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Homotaurine, a safe blood-brain 
barrier permeable GABAA-R-specific 
agonist, ameliorates disease in 
mouse models of multiple sclerosis
Jide Tian, Hoa Dang, Martin Wallner, Richard Olsen & Daniel L. Kaufman
There is a need for treatments that can safely promote regulatory lymphocyte responses. T cells express 
GABA receptors (GABAA-Rs) and GABA administration can inhibit Th1-mediated processes such as 
type 1 diabetes and rheumatoid arthritis in mouse models. Whether GABAA-R agonists can also inhibit 
Th17-driven processes such as experimental autoimmune encephalomyelitis (EAE), a model of multiple 
sclerosis (MS), is an open question. GABA does not pass through the blood-brain barrier (BBB) making 
it ill-suited to inhibit the spreading of autoreactivity within the CNS. Homotaurine is a BBB-permeable 
amino acid that antagonizes amyloid fibril formation and was found to be safe but ineffective in 
long-term Alzheimer’s disease clinical trials. Homotaurine also acts as GABAA-R agonist with better 
pharmacokinetics than that of GABA. Working with both monophasic and relapsing-remitting mouse 
models of EAE, we show that oral administration of homotaurine can (1) enhance CD8+CD122+PD-1+ 
and CD4+Foxp3+ Treg, but not Breg, responses, (2) inhibit autoreactive Th17 and Th1 responses, and 
(3) effectively ameliorate ongoing disease. These observations demonstrate the potential of BBB-
permeable GABAA-R agonists as a new class of treatment to enhance CD8+ and CD4+ Treg responses 
and limit Th17 and Th1-medaited inflammation in the CNS.
There is an unmet need for clinical treatments that can safely limit the progression of chronic inflammatory disor-
ders. This is especially true for T-cell mediated autoimmune disorders such as type 1 diabetes (T1D), rheumatoid 
arthritis (RA), and multiple sclerosis (MS) in which inhibiting established autoimmune responses against the 
target tissue may require life-time treatment.
Rodent and human T cells express receptors for the nonprotein amino acid γ-aminobutyric acid (GABA)1–5. 
GABA is a commonly used neurotransmitter in the CNS and its neurobiological activities in brain development 
and function have been extensively studied. The immunobiological activities of GABA, however, are just begin-
ning to be elucidated. There are two types of GABA-receptors (GABA-Rs) that are encoded by distinct gene fam-
ilies and their activation induces different pathways; GABAA-Rs are fast-acting chloride channels and GABAB-Rs 
are slow-acting G-protein coupled receptors6,7. Rodent and human T cells expresses functional GABAA-Rs but 
appear unresponsive to GABAB-R-specific agonists1,3–5. In mice, GABA administration limited delayed type 
hypersensitivity (DTH) responses and inhibited or reversed disease in models of T1D1,2,5,8–10, RA11, and limited 
inflammation and disease in type 2 diabetes models12–14. Studies of the mechanisms underlying those observa-
tions revealed that GABA treatment inhibited the development of autoreactive Th1 responses while also increas-
ing CD4+ Tregs. These preclinical studies provided the basis for an ongoing clinical trial in which GABA is being 
given to individuals newly diagnosed with T1D (NCT02002130).
Whether this therapeutic approach can be extended to EAE and potentially to MS is unclear. First, while auto-
reactive Th1 cells are thought to be primary drivers of DTH responses, T1D, and RA disease progression, autore-
active Th17 responses are thought to play a major pathogenic role in EAE and MS15,16. Second, while DTH, T1D, 
and RA are mediated by peripheral autoimmune T cell responses, disease relapses in EAE and MS are thought 
be due to the spreading of T cell autoreactivity within the CNS17–19. Orally administered GABA, however, has 
little to no ability to pass through the BBB20, making it ill-suited to inhibit the spreading of T cell autoreactivities 
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within the CNS. To circumvent that limitation, Steinman and colleagues21 showed that two clinically applica-
ble BBB-permeable anti-seizure medications, topiramate and vigabatrin, that increase GABAergic tone, inhib-
ited EAE. Topiramate, however, primarily affects other ion channels (e.g., sodium and calcium channels) and 
enzymes22,23 and vigabatrin does not bind to GABA-Rs but rather inhibits GABA transaminase23, and both drugs 
have multiple adverse effects. Other studies have shown that the anti-alcohol dependence drug acamprosate, 
which has structural similarities with GABA, can limit EAE24, but recent studies indicate that acamprosate does 
not act directly through GABAA-Rs25,26. Benzodiazepines and barbiturates are BBB-permeable GABAA-R positive 
allosteric modulators that can potentiate the opening of GABAA-R chloride channels, but only after a GABAA-R 
agonist opens the channel, and these drugs can be addictive. Accordingly, there is a need for BBB-permeable 
GABAA-R-specific agonists with excellent safety profiles that could potentially provide a new class of drugs for 
limiting inflammation in the CNS.
Homotaurine is a natural amino acid found in algae. Homotaurine emerged as a leading candidate from a 
screen for compounds that physically interfered with the ability of amyloid peptide to form fibrils in vitro27,28. 
Subsequent studies found that oral homotaurine can pass through the BBB and limit amyloid plaque deposi-
tion in the brain of transgenic mice that over-expressed human amyloid protein27,28. Based on these observa-
tions, homotaurine (also known as Tramiprosate or Alzhemed) was tested in a large double-blind randomized 
phase III clinical trial for its ability to slow cognitive loss over 1.5 years in patients with Alzheimer’s disease29,30. 
While homotaurine treatment was found to not slow cognitive decline, it had an excellent safety profile in this 
long-term study. Recently, it has become appreciated that homotaurine can also act as a GABAA-R-specific ago-
nist. Homotaurine has >3-fold higher affinity for classical GABAA-Rs and a longer half-life than GABA in plasma 
(≈3 hours vs. 20 minutes for GABA after intravenous or intraperitoneal injection)28,31–34. Homotaurine’s pharma-
cokinetic properties, along with its safety record in humans, make it an appealing candidate for treating inflam-
mation in the CNS. We therefore tested whether homotaurine could be repurposed for treating murine EAE. 
After finding homotaurine was effective in two different murine EAE models, we studied the treatment’s poten-
tial therapeutic mechanisms and observed, for the first time, that in addition to promoting CD4+Foxp3+ Treg 
responses, GABAA-R activation also enhances CD8+CD122+PD-1+ Treg responses and inhibits Th17 responses. 
Thus, GABAA-Rs are a new druggable target for enhancing CD8+ Treg responses and inhibiting Th17 responses 
in inflammation-related disorders.
Results and Discussion
We first tested the ability of homotaurine to limit disease progression in the chronic model of EAE that was 
induced by immunizing C57BL/6 mice with a myelin oligodendrocyte glycoprotein peptide (MOG35–55)35. Eleven 
to thirteen days after receiving the encephalitic regimen, all of the mice began to develop EAE. When an animal 
reached an EAE severity score of 1 it was randomly assigned to receive plain drinking water, or water containing 
homotaurine (0.25 mg/ml) for the rest of the observation period. This homotaurine dose was chosen based on our 
dosing studies of homotaurine’s ability to reverse disease in newly diabetic NOD mice (manuscript in prepara-
tion). Control and homotaurine-treated groups of mice drank similar amounts of water each day (≈4 ml/mouse/
day). While the control group of mice quickly progressed to more severe EAE, the homotaurine treatment group 
of mice remained at low clinical score of EAE (Fig. 1A).
We next tested homotaurine treatment in a relapsing-remitting model of EAE that was induced by immuniz-
ing SJL mice with a proteolipid protein peptide (PLP139–151)36. Ten to 12 days after receiving the encephalitic reg-
imen, all of the mice began to develop EAE. When an animal reached an EAE severity score of 1 it was randomly 
assigned to receive plain drinking water, or water containing homotaurine (0.25 mg/ml) for the rest of the study. 
Control mice displayed classical relapsing-remitting EAE. Homotaurine-treated mice exhibited a reduced mean 
EAE severity throughout the observation period compared to those given plain water, and eventually displayed 
almost complete remission (Fig. 1B). Histological analysis of their brains and spinal cords revealed reduced mon-
onuclear cell infiltration and areas of myelin loss in the cerebellum and spinal cords of homotaurine-treated mice 
(Fig. 1C). Thus, treatment with homotaurine after the clinical onset of EAE inhibited disease progression in both 
monophasic and relapsing-remitting mouse models of MS. Previous studies using GABA to inhibit T1D and RA 
in mouse models could not distinguish the contributions of GABAA-Rs versus GABAB-Rs to those observations. 
Our results using homotaurine point directly to GABAA-R-mediated pathways as major components of GABA’s 
anti-inflammatory effects.
To begin to understand the basis for homotaurine’s therapeutic effects, we next examined homotaurine’s effects 
on lymphocytes since T cells are the major mediators of EAE and MS. SJL mice were immunized with PLP139–151 
and 10 days later (when most mice had an EAE score of about 1), the mice were given plain water or water con-
taining homotaurine (0.25 mg.ml) continuously for five days after which their splenic T cells were analyzed by 
ELISPOT. Consistent with previous studies of GABA treatment2,5,8,10,11, we observed that homotaurine treatment 
significantly decreased the frequency of splenic IFNγ (Th1) responses, but increased IL-10-secreting responses 
to PLP139–151 (Fig. 2). In addition, we show for the first time, that GABAA-R activation significantly reduces the 
frequency of PLP139–151-reactive IL-17A (Th17) spot-forming colonies (SFC) (Fig. 2). These IL-17A SFC represent 
antigen-specific activated/memory CD4+ T cells since peptide 13mers do not stimulate CD8+ T cells effectively, 
and it has been demonstrated in the PLP139–151/SJL model that IL-17 secreting SFC arise from CD4+ cells and not 
other cell types37. Homotaurine had no effect on Th2 frequencies (data not shown).
GABA treatment can promote CD4+ Treg responses in mice8,12. It is unknown whether GABAA-R activation 
might also modulate CD8+CD122+PD-1+ and CD8+CD122+PD-1− regulatory T cells or IL-10-secreting Bregs 
which can play crucial roles in inhibiting inflammation and T cell autoimmunity. We found that the percentages 
of splenic CD4+Foxp3+ Tregs (Fig. 3A) and CD8+CD122+PD-1+, but not CD8+CD122+PD-1−, Tregs (Fig. 3B,C) 
in the homotaurine-treated mice were significantly higher than in the controls. There was no significant differ-
ence in the frequency of splenic CD19+IL-10+ Bregs (data not shown).
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To test the inhibitory function of CD8+CD122+PD-1+ and CD8+CD122+PD-1− Tregs, SJL mice were immu-
nized with PLP139–151 and 10 days later, they were randomized to receive homotaurine (0.25 mg/ml) through their 
drinking water, or plain water for the next six days. Their splenic CD8+CD122+PD-1+ and CD8+CD122+PD-1− 
Tregs were sorted by flow cytometry and mixed with lymph node mononuclear cells from PLP139–151-immunized 
SJL mice for proliferation assays. Co-culture with CD8+CD122+PD-1+ Tregs, but not CD8+CD122+PD-1− Tregs, 
from either homotaurine-treated or control (plain water)-treated mice significantly inhibited the proliferation 
of responders in a dose-dependent manner (Fig. 3D). The inhibitory effect of CD8+CD122+PD-1+ cells from 
homotaurine-treated mice was comparable to those from control mice, indicating that homotaurine treat-
ment did not significantly alter their suppressive activity. These data, together with the increased frequency of 
CD4+Foxp3+ and CD8+CD122+PD-1+ Tregs in the homotaurine-treated mice indicate that CD4+Foxp3+ and 
CD8+CD122+PD-1+ Tregs play an important role in inhibiting the pathogenic T cell autoimmunity, contributing 
to the decreased severity of EAE.
Figure 1. Homotaurine inhibits EAE progression after the onset of symptoms in both monophasic and 
relapsing-remitting mouse models of MS. (A) C57BL/6 mice were immunized with MOG35–55 and monitored 
daily for clinical signs of EAE as described in Methods. Eleven to thirteen days post-immunization all of the 
mice developed EAE. When the mice reached an EAE score of 1 they were randomized to receive plain water 
or water containing homotaurine (0.25 mg/ml). Graph shows mean EAE scores ± SEM for mice that received 
plain water (circles) and homotaurine (triangles) after EAE onset. N = 5 mice/group, overall p = 0.01, by 
Kruskal-Wallis analysis. (B) SJL mice were immunized with PLP139–151 and ten to twelve days later all of the mice 
develeoped clinical symptoms. When the mice reached an EAE score of 1 they were randomized to receive plain 
water or water containing homotaurine. Graph shows mean EAE scores ± SEM for mice that received plain 
water (circles) or homotaurine (triangles) continuously after EAE onset. N = 8 mice/group, *p < 0.05, overall 
p < 0.01. (C) Spinal cord (left panel) and cerebellum (right panel) in control and homotaurine-treated PLP139–151 
immunized SJL mice. Twenty-seven days after treatment, adjacent sections were stained with hematoxylin and 
eosin (H &E, top row) and luxol fast blue or black gold (bottom row). Arrow in H&E stained sections indicates 
infiltrates. Inserts in black gold stained cerebellum images show boxed areas magnified 1.5X revealing greater 
myelination and fine myelin fibers in homotaurine-treated mice (arrows). Left panel scale bar = 1 mm, right 
panel scale bar = 250 µm.
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Very few of the many drugs that can inhibit EAE successfully translated to the clinic. Factors that contribute 
to this failure include; (1) inherent differences between EAE and MS, (2) toxicity or side-effects in humans, and 
(3) supra-physiological doses were used in the EAE studies. In regard to those issues, human T cells express 
GABAA-Rs whose activation can limit PBMC inflammatory responses3–5,38, homotaurine appears to be safe for 
long-term human use, and using FDA guidelines (www.fda.gov/downloads/Drugs/…/Guidances/UCM078932.
pdf) for scaling mouse doses to the equivalent human dosage, the homotaurine dose we used to inhibit EAE was 
6–10-fold lower than that used in the Alzheimer’s disease clinical trials.
Murine and human T cells express relatively high levels of transcripts encoding the δ and ρ2 subunits of 
GABAA-Rs2–5,38. The δ and ρ2 subunits are of particular interest because thay are found in “extrasynaptic” 
GABAA-Rs that can be orders of magnitude more sensitive to GABA than the typical GABAA-Rs subtypes that 
are clustered in neuronal synapses39–44. These δ and /or ρ2 subunits may confer T cells with sensitivity to low levels 
of GABA and contribute to CNS “immunological privilege”. In this scenario, endogenous CNS GABA may help 
regulate the low-frequency CNS-reactive T cells that spontaneously activate under normal conditions, but it is 
insufficient to regulate the large number of autoreactive T cells that are experimentally activated in EAE. As we 
show here, administration of a BBB-permeable high-affinity GABAA-R agonist is capable of limiting CNS auto-
reactivity under those conditions. Additionally, homotaurine may have acted on antigen presenting cells (APC) 
such as macrophages, dendritic cells, and microglia that contribute to EAE pathogenesis21,45,46. These APC also 
express GABAA-Rs and GABAA-R agonists have been shown to inhibit their inflammatory activity11,21,47–49.
In summary, our findings provide insights into the actions of GABAA-Rs on lymphocytes, as well as a 
proof-of-principle for a potential new class of drug treatment for enhancing Treg responses and limiting autore-
active Th17 cells. Our findings have potential for treating MS and may have broader applications for ameliorating 
other inflammation-related disorders of the CNS.
Methods
EAE induction and treatment. All experimental protocols were approved by the UCLA Animal Protection 
Committee and carried out in accordance with relevant guidelines. Nine to ten weeks old female C57BL/6 or SJL 
mice were obtained from the Jackson Laboratory and housed in a specific pathogene-free facility with free access 
of food and water. C57BL/6 mice were immunized subcutaneously with MOG35–55 (200 µg) in 50% IFA contain-
ing Mycobacterium tuberculosis H37R (5 mg/ml, Difco) in multiple sites near the base of their tail on day 1 and 
injected intraperitoneally with pertussis toxin (200 ng/mouse) on day 0 and 2. Individual SJL mice were immu-
nized with PLP139–151 (100 µg/mouse), as described above, but without pertussis toxin injection. The mice were 
monitored for EAE onset daily: 0, no disease; 1, limp tail; 2, hind limb weakness; 3, complete hind limb paralysis; 
4, quadriplegia; and 5, death. Mice that were in between the clear-cut gradations were scored intermediate in 
increments of 0.5. When the mice developed EAE with a score of 1 at 10–12 days post-immunization, they were 
randomized to receive plain water or water containing homotaurine (0.25 mg/ml (Sigma-Aldrich A76109), an 
optimal dose based on preliminary studies of T1D prevention in NOD mice).
Histology. Mice were perfused with 4% paraformaldehyde in 0.1 M phosphate buffer, fixed overnight at 4 °C, 
cryoprotected and frozen. The brain and spinal cord cryostat sections (10 and 20 μm) were directly mounted on 
slides or collected into PBS with 0.06% NaN3. The sections were mounted onto Superfrost + slides and stained 
Figure 2. Homotaurine treatment at time of clinical EAE onset reduces the frequency of autoreactive IL-
17A- and IFNγ-secreting T cell responses, while increasing IL-10-secreting responses. Mice were PLP139–151 
immunized and after reaching an EAE score of 1, they received plain water or homotaurine for five days. Splenic 
T cells were isolated from individual mice and the percentages of IL-17A, IFNγ and IL-10 secreting T cells 
responding to PLP139–151 were measured by ELISPOT. Data shown are the mean SFC ± SEM of each group of 
mice (n = 5 per group) from two separate experiments. IL-4 responses to PLP139–151 were at background levels 
(data not shown). Wells containing cells from control or homotaurine-treated mice that were incubated with 
medium alone had 0–5 SFC. Pairwise comparisons were performed by 2-tailed Student’s t test. **p < 0.01 vs. the 
controls.
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with H&E or Black Gold II. Some mouse brain and spinal cord tissues were paraffin-embedded after fixation and 
stained with H&E or luxol fast blue. The sections were imaged under a light microscope.
ELISPOT assays for IFN, IL-17A, IL-10. SJL mice were immunized with 100 µg PLP139–151 in 50% IFA con-
taining 5 mg/ml Mycobacterium tuberculosis H37R. When the mice developed EAE with a score of 1, the mice 
were randomized and received plain water or water containing 0.25 mg/ml homotaurine for 5 days. Their splenic 
mononuclear cells were isolated and the frequency of IFNγ, IL-17A, IL-4 and IL-10-secreting T cells respond-
ing to antigens were determined by ELISPOT as described previously10 with the addition that rat anti-mouse 
interleukin IL-17 (4 μg/ml, clone TC-11-18H10, BD Biosciences) and biotin-conjugated anti-IL-17 (5.0 μg/ml; 
Pharmingen, clone TC-11-8H4.1) were used as capture and detection antibodies for IL-17A, respectively. Briefly, 
Figure 3. Homotaurine treatment enhances CD4+ and CD8+ Treg responses in mice. SJL mice were 
immunized with PLP139–151 in 50% CFA and when the mice developed EAE with a score of 1, they were 
randomized and provided with plain water and water containing 0.25 mg/ml homotaurine for five days. 
The percentages of splenic (A) CD4+Foxp3+, (B,C) CD8α+CD122+ and CD8α+CD122+PD-1+ Tregs were 
determined by flow cytometry. The cells were gated first on living lymphocytes and CD4+ or CD8+ and the 
percentages of CD4+Foxp3+, CD8α+CD122+PD-1− and CD8α+CD122+PD-1+ Tregs were analyzed. Data are 
representative flow cytometry charts or expressed as the mean ± SEM of each group of mice (n = 5 per group) 
from two separate experiments. *p < 0.05, **p < 0.01 vs. the controls. (D) Splenic CD8+CD122+PD-1+ and 
CD8+CD122+PD-1− Tregs were sorted by flow cytometry and mixed with lymph node mononuclear cells from 
PLP139–151-immunized SJL mice at the indicated ratios and assessed for PLP139–151-stimulated T cell proliferation. 
Data are expressed as mean ± SD of each group of cells. The cultures with responders in medium alone served 
the negative controls (with CPM of 850–940) and peptide-stimulated cultures without any inhibitor provided 
positive controls. Additional positive control cells were stimulated with PPD or anti-CD3 (with CPM of 20821–
26759). *p < 0.05, **p < 0.01 vs. the peptide-stimulated positive controls.
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splenic mononuclear cells (106/well) were stimulated in duplicate with PLP139-151 (15 µg/ml), positive control 
PPD (5 µg/ml) or mouse serum albumin (50 µg/ml, Sigma) in HL-1 medium for 24 or 48 h. The spot forming 
colonies (SFC) in each well were counted in a blinded manner.
FACS. When PLP139–151 immunized mice developed EAE with a score of 1, they were randomized to receive 
plain water or water containing 0.25 mg/ml homotaurine for 5 days. Splenic mononuclear cells (106/tube) from 
the control and homotaurine-treated groups were treated with 1 µg anti-CD16/anti-CD32 and stained with 
FITC-anti-CD8α, APC-anti-CD122 and PE-anti-PD-1. After being washed, the frequency of CD8+CD122+PD1− 
and CD8+CD122+PD-1+ regulatory T cells was determined by flow cytometry. In addition, splenic mononu-
clear cells (106/tube) were stained with FITC-anti-CD4, fixed, permeabilized and intracellularly stained with 
PE-anti-Foxp3. The frequency of CD4+Foxp3+ Tregs was determined by flow cytometry. Moreover, splenic mon-
onuclear cells (106/tube) were stimulated with 50 nM PMA and 1 µM ionomycine (Sigma) for 2 h and in the 
presence of monensin for another 3 h. The cells were stained with FITC-anti-CD19, fixed, permeabilized and 
intracellularly stained with PE-anti-IL-10. The cells with isotype controls served as the negative controls. The 
frequency of CD19+IL-10+ Bregs was determined by flow cytometry.
Functional assessment of CD8+ Treg suppressor activity. Female SJL mice were injected with 
200 µg PLP139–51 in 50% CFA and nine days later, the mice were randomized and provided with, or without, 
homotaurine in their drinking water (0.25 mg/ml) for 6 days. The mice were then sacrificed, their splenic mon-
onuclear cells were isolated, and CD8+ T cells were enriched by negative selection using the Majosort mouse 
CD8 T cell isolation kit (BioLegend, San Diego). The isolated CD8+ T cells were stained with FITC-anti-CD8, 
APC-anti-CD122 and PE-anti-PD-1 (BioLegend). The CD8+CD122+PD-1+ and CD8+CD122+PD-1− Tregs were 
sorted by flow cytometry and used as inhibitors. In addition, SJL mice were immunized with 100 µg PLP139–151 
in 50% CFA in their footpads and nine days later, their draining lymph node mononuclear cells were isolated 
and used as responders. To test the inhibitory function of CD8+ Tregs, lymph node mononuclear cells (1 × 105 
cells/well) were mixed in triplicate with CD8+CD12+PD-1+ or CD8+CD122+PD-1− Tregs from either control 
or homotaurine-treated mice at ratios of 0.2, 0.1 or 0.05 (inhibitors to responders) and stimulated with PLP139–151 
(20 µg/ml) for 96 hours. Some responders received medium alone (negative control) and other responders were 
stimulated with peptide antigen in the absence of inhibitory cells (positive control). Moreover, some responders 
were stimulated with PPD (10 µg/ml) or anti-CD3 (1 µg/ml) and served as additional positive controls. During the 
last 16-hour culture, individual wells of cells were exposed to 1 µci 3H-thymidine and the 3H-thymidine uptakes 
were measured by a β-counter.
Statistics. EAE scores were evaluated using Kruskal-Wallis test. Pairwise comparisons were performed by 
2-tailed Student’s t test. P < 0.05 was considered statistically significant.
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